Grand Pharma entered into a product cooperation agreement with Pediatrix Therapeutics Technology (Shanghai) Co. Ltd.* (祐兒醫藥科技（上海）有限公司, Pediatrix Therapeutics) recently. We will acquire the exclusive commercialization rights in Mainland China through cooperative channels and the nonexclusive commercialization rights in Hong Kong Special Administrative Region for Neffy®, the world’s first adrenaline nasal spray for emergency treatment of type I allergic reactions (including severe allergic reactions) in adults and children weighing over 30kg (2mg specification) and children weighing 15-30kg (1mg specification). This collaboration is led by Grand Pharma (Beijing) Co., Ltd.* (遠大醫藥（北京）有限公司), a subsidiary of the Group, and plans to achieve localized production within 24 months after the product is approved.
Pediatrix Therapeutics’ core product, Neffy®, is the first non-injectable treatment product approved by the United States Food and Drug Administration (FDA) for the treatment of type I allergic reactions (including severe allergic reactions). It uses an innovative nasal spray delivery method.
Its pivotal clinical study results show that subjects treated with Neffy® or approved adrenaline injection products had comparable blood concentrations of a
